FIELD: medicine.
SUBSTANCE: technique involves performing a patient's oral fluid analysis with the patient's oral fluid sampled prior to or not less than 30 minutes following meals, centrifuging the patient's oral fluid at 3000 rpm for 15 minutes, diluting the oral fluid with physiological solution in a ratio of 1:100 and centrifuging once again at 3000 rpm for 15 minutes, placing the prepared patient's oral fluid material into a tray and performing a standard enzyme immunoassay of monoclonal antibodies; that is followed by the findings analysis; the oral fluid is sampled from the patient for the purpose of qualitative differential instant diagnosis of the parotid gland growths as shown by the oral fluid biomarkers; the biomarker is matrix metal metalloproteinase 8 (MMP 8) to be measured in the patient's oral fluid; the qualitative content of the biomarker MMP 8 of the clinical reference oral fluid biomarker is 23.85-39.65 ng/ml, and if MMP 8 is found in an amount of 611.32-792.00 ng/ml, the parotid gland adenoma is diagnosed, and if MMP 8 is found in an amount of 496.86-570.33 ng/ml, the parotid gland cancer is diagnosed; matrix metalloproteinase 9 (MMP 9) is measured in the patient's oral fluid; the clinical reference oral fluid biomarker makes 108.14-180.47 ng/ml; if MMP9 is found in an amount of 326.43-458.23 ng/ml, the parotid gland adenoma is diagnosed, and if MMP9 making 782.13-906.60 ng/ml enables diagnosing the parotid gland cancer; the derived values of the patient's oral fluid biomarkers are used to predict a therapeutic approach to the patient.
EFFECT: higher accuracy, sensitivity of the differential instant diagnosis, high probability of detection of benign and malignant new growths in the patient's body both at the early stages, and at the later stages, simplified preparation of the patient within the time frame for sampling and storing the diagnostic material.
3 cl, 6 ex
